SMNR (Semnur Pharmaceuticals) Total Operating Expense: $164.33 Mil (TTM As of Mar. 2026)


SMNR Semnur Pharmaceuticals Inc SMNR
8 GF Score
Price $0.68
View Full Analysis

What is Semnur Pharmaceuticals Total Operating Expense?

Semnur Pharmaceuticals SMNR -9.63% 8 Total Operating Expense is $164.33 Mil as of Mar. 2026. GuruFocus rates SMNR with a GF Score™ of 8/100.

Semnur Pharmaceuticals's Total Operating Expense for the three months ended in Mar. 2026 was $4.58 Mil. Semnur Pharmaceuticals's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $164.33 Mil.

Semnur Pharmaceuticals Total Operating Expense Related Terms

Semnur Pharmaceuticals Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Semnur Pharmaceuticals's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Semnur Pharmaceuticals Total Operating Expense Chart

Semnur Pharmaceuticals Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Operating Expense
3.77 3.26 4.69 160.42

Semnur Pharmaceuticals Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.67 1.00 152.59 6.16 4.58
SMNR
8GF Score
Semnur Pharmaceuticals Inc SMNR
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Semnur Pharmaceuticals Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $164.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $164.33 Mil mean?
Semnur Pharmaceuticals (SMNR) has a Total Operating Expense of $164.33 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Semnur Pharmaceuticals and its competitors.
Is Semnur Pharmaceuticals' Total Operating Expense too high?
Semnur Pharmaceuticals' current Total Operating Expense is $164.33 Mil. Overall, Semnur Pharmaceuticals has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Semnur Pharmaceuticals' Total Operating Expense compare to CNTB and ENLV?
Semnur Pharmaceuticals' Total Operating Expense of $164.33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Semnur Pharmaceuticals and its competitors. Semnur Pharmaceuticals's current Total Operating Expense is $164.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Semnur Pharmaceuticals stock overvalued right now?
Semnur Pharmaceuticals (SMNR) has a current Total Operating Expense of $164.33 Mil. The current Total Operating Expense is $164.33 Mil. Semnur Pharmaceuticals' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Semnur Pharmaceuticals (SMNR), the current Total Operating Expense is $164.33 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Semnur Pharmaceuticals Business Description

Address 960 San Antonio Road, Palo Alto, CA, USA, 94303
Semnur Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its main product candidate, SP-102 (10 mg, dexamethasone sodium phosphate viscous gel), is being developed as a non-opioid novel injectable corticosteroid gel formulation for patients with moderate to severe LRP (also known as sciatica), containing no preservatives, surfactants, solvents, or particulates.
8GF Score

Get the complete analysis for SMNR

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.68
Price